Mendelian randomization study reveals gut microbiota influences risk of diffuse large B-cell lymphoma, suggesting potential therapeutic targets.
This MR study provides evidence that specific gut microbial taxa and microbiota-derived metabolites may causally influence the risk of DLBCL.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: